We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

54 hedge funds and large institutions have $31.3M invested in Tempest Therapeutics in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2K | Put options by funds: $1K

14% less funds holding

Funds holding: 63 → 54 (-9)

25% less capital invested

Capital invested by funds: $41.9M → $31.3M (-$10.6M)

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

Holders
54
Holders Change
-9
Holders Change %
-14.29%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
9
Reduced
16
Closed
23
Calls
$2K
Puts
$1K
Net Calls
+$1K
Net Calls Change
-$19K

Top Buyers

Rank Fund Capital Flow
1
Legal & General Group
Legal & General Group
United Kingdom
+$652K
2
ACA
Avoro Capital Advisors
New York
+$453K
3
BC
Broadfin Capital
New York
+$398K
4
Millennium Management
Millennium Management
New York
+$326K
5
ECM
Element Capital Management
New York
+$207K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.04M
2
GC
GMT Capital
Georgia
-$1.42M
3
State Street
State Street
Massachusetts
-$656K
4
Northern Trust
Northern Trust
Illinois
-$385K
5
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$249K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$8.28M -$46.5K -11 -0.6%
EC
2
EcoR1 Capital
California
$5.48M – – –
Jennison Associates
3
Jennison Associates
New York
$3.42M +$8.46K +2 +0.3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.36M -$207K -49 -9%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$2M – – –
Franklin Resources
6
Franklin Resources
California
$992K – – –
SM
7
Sabby Management
Florida
$795K +$123K +29 +20%
BlackRock
8
BlackRock
New York
$729K -$2.04M -481 -75%
Legal & General Group
9
Legal & General Group
United Kingdom
$713K +$652K +154 +5,133%
Millennium Management
10
Millennium Management
New York
$652K +$326K +77 +117%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$648K +$157K +37 +35%
TS
12
Third Security
Virginia
$582K – – –
ACA
13
Avoro Capital Advisors
New York
$489K +$453K +107 New
BC
14
Broadfin Capital
New York
$429K +$398K +94 New
BCM
15
BBT Capital Management
Texas
$396K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$354K -$93.1K -22 -22%
Wells Fargo
17
Wells Fargo
California
$256K +$50.8K +12 +27%
AIC
18
AWM Investment Company
New York
$234K – – –
ECM
19
Element Capital Management
New York
$225K +$207K +49 New
HCM
20
Howland Capital Management
Massachusetts
$183K – – –
PP
21
Paloma Partners
Connecticut
$180K +$165K +39 New
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$176K +$76.2K +18 +86%
Morgan Stanley
23
Morgan Stanley
New York
$163K -$80.4K -19 -35%
LP
24
LMR Partners
United Kingdom
$145K +$135K +32 New
NCMW
25
Northern Capital Management (Wisconsin)
Wisconsin
$143K – – –
1
2 3 4

TPST Hedge Fund Activity: Q2 2017 in Review

54 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2017, worth a combined $31.3M — down 25% from $41.9M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of TPST and 14 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 9 added.

The largest buyer was Legal & General Group, adding an estimated $652K. The largest seller was BlackRock, cutting an estimated $2.04M.

  • 54 institutional investors held Tempest Therapeutics (TPST) as of Q2 2017, down from 63 in Q1 2017.
  • Funds reported $31.3M of Tempest Therapeutics stock for Q2 2017, down 25% quarter-over-quarter.
  • 14 funds opened new Tempest Therapeutics positions in Q2 2017 and 23 closed out, a net change of -9 holders.
  • The largest Tempest Therapeutics buyer in Q2 2017 was Legal & General Group, an estimated $652K added.
  • The largest Tempest Therapeutics seller in Q2 2017 was BlackRock, an estimated $2.04M sold.

Based on aggregated 13F filings for Q2 2017.